Yabao Pharmaceutical Group Co Ltd (600351.SS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE000001CM5
Yabao Pharmaceutical Group Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.69 bn CNY | 2.24 bn CNY |
| Gross profit | 1.36 bn CNY | 1.18 bn CNY |
| Operating income | 299.95 m CNY | 349.71 m CNY |
| EBIT | 297.79 m CNY | 375.91 m CNY |
| Net income | 242.69 m CNY | 320.01 m CNY |
| Diluted EPS – continuing operations | 0.34 CNY | 0.46 CNY |
Full history since 1999, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Yabao Pharmaceutical Group Co Ltd
Yabao Pharmaceutical Group Co., Ltd engages in the research and development, production, and sale of pharmaceutical products in China and internationally. It provides pediatric products, cardiovascular and cerebrovascular products, endocrine products, analgesics, psychotropic drugs, women's health products, patches, and general health products. The company was founded in 1978 and is based in Beijing, China.
More stocks
- Hemnet Group AB (publ) (HEM.ST)
- Henan Hengxing Science & Technology Co Ltd (002132.SZ)
- Cancom (COK.DE)
- Winall Hi tech Seed (300087.SZ)
- Nuvectis Pharma, Inc. (NVCT)
- LivsMed (491000.KQ)
- Hellenic Exchanges Athens Stock Exchange SA (EXAE.AT)
- China Resources and Environment Co Ltd (600217.SS)
- Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096.SZ)
- Faraday Copper Corp (FDY.TO)
- JAFCO Group Co Ltd (8595.T)
- VP Bank AG (VPBN.SW)
Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.